Newamsterdam Pharma Stock Price Prediction

NAMS Stock   19.85  0.95  4.57%   
The RSI of NewAmsterdam Pharma's share price is above 70 at this time. This indicates that the stock is becoming overbought or overvalued. The idea behind Relative Strength Index (RSI) is that it helps to track how fast people are buying or selling NewAmsterdam, making its price go up or down.

Oversold Vs Overbought

78

 
Oversold
 
Overbought
The successful prediction of NewAmsterdam Pharma's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of NewAmsterdam Pharma and does not consider all of the tangible or intangible factors available from NewAmsterdam Pharma's fundamental data. We analyze noise-free headlines and recent hype associated with NewAmsterdam Pharma, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting NewAmsterdam Pharma's stock price prediction:
EPS Estimate Next Quarter
(0.48)
EPS Estimate Current Year
(2.15)
EPS Estimate Next Year
(1.89)
Wall Street Target Price
37
EPS Estimate Current Quarter
(0.50)
Using NewAmsterdam Pharma hype-based prediction, you can estimate the value of NewAmsterdam Pharma from the perspective of NewAmsterdam Pharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in NewAmsterdam Pharma to buy its stock at a price that has no basis in reality. In that case, they are not buying NewAmsterdam because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

NewAmsterdam Pharma after-hype prediction price

    
  USD 19.92  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out NewAmsterdam Pharma Basic Forecasting Models to cross-verify your projections.
For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.
Intrinsic
Valuation
LowRealHigh
17.3520.9824.61
Details
9 Analysts
Consensus
LowTargetHigh
22.9025.1627.93
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.63-0.54-0.46
Details

NewAmsterdam Pharma After-Hype Price Prediction Density Analysis

As far as predicting the price of NewAmsterdam Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in NewAmsterdam Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of NewAmsterdam Pharma, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

NewAmsterdam Pharma Estimiated After-Hype Price Volatility

In the context of predicting NewAmsterdam Pharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on NewAmsterdam Pharma's historical news coverage. NewAmsterdam Pharma's after-hype downside and upside margins for the prediction period are 16.29 and 23.55, respectively. We have considered NewAmsterdam Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
19.85
19.92
After-hype Price
23.55
Upside
NewAmsterdam Pharma is not too volatile at this time. Analysis and calculation of next after-hype price of NewAmsterdam Pharma is based on 3 months time horizon.

NewAmsterdam Pharma Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as NewAmsterdam Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading NewAmsterdam Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with NewAmsterdam Pharma, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.41 
3.63
  0.07 
  0.10 
10 Events / Month
11 Events / Month
In about 10 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
19.85
19.92
0.35 
2,269  
Notes

NewAmsterdam Pharma Hype Timeline

NewAmsterdam Pharma is now traded for 19.85. The entity has historical hype elasticity of 0.07, and average elasticity to hype of competition of -0.1. NewAmsterdam is expected to increase in value after the next headline, with the price projected to jump to 19.92 or above. The average volatility of media hype impact on the company the price is over 100%. The price appreciation on the next news is projected to be 0.35%, whereas the daily expected return is now at 0.41%. The volatility of related hype on NewAmsterdam Pharma is about 1455.64%, with the expected price after the next announcement by competition of 19.75. The company reported the previous year's revenue of 12.76 M. Net Loss for the year was (160.27 M) with profit before overhead, payroll, taxes, and interest of 0. Given the investment horizon of 90 days the next expected press release will be in about 10 days.
Check out NewAmsterdam Pharma Basic Forecasting Models to cross-verify your projections.
For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

NewAmsterdam Pharma Related Hype Analysis

Having access to credible news sources related to NewAmsterdam Pharma's direct competition is more important than ever and may enhance your ability to predict NewAmsterdam Pharma's future price movements. Getting to know how NewAmsterdam Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how NewAmsterdam Pharma may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
GLUEMonte Rosa Therapeutics(0.74)8 per month 3.74  0.09  8.10 (8.18) 102.66 
IVAInventiva Sa(0.08)3 per month 4.09  0.03  7.26 (6.92) 49.76 
CGEMCullinan Oncology LLC(0.23)9 per month 0.00 (0.16) 5.88 (7.24) 17.85 
CMPXCompass Therapeutics(0.15)4 per month 4.24  0.09  11.19 (5.92) 29.38 
REPLReplimune Group 0.02 9 per month 3.34  0.08  8.25 (6.02) 46.30 
CRNXCrinetics Pharmaceuticals(1.21)11 per month 2.47 (0.01) 3.67 (3.45) 16.75 
PRTCPureTech Health PLC(1.48)2 per month 0.00 (0.05) 4.06 (5.57) 14.97 
MRUSMerus BV 1.06 7 per month 0.00 (0.16) 3.08 (2.83) 10.85 
MLYSMineralys Therapeutics, Common 0.14 8 per month 3.42  0  6.27 (5.79) 20.98 
ELYMEliem Therapeutics 0.25 4 per month 0.00 (0.19) 6.21 (9.35) 34.87 
ANEBAnebulo Pharmaceuticals(0.02)5 per month 0.00 (0.02) 8.61 (11.48) 76.00 
JANXJanux Therapeutics(1.65)9 per month 2.62 (0.02) 6.87 (4.58) 15.08 
RZLTRezolute(0.28)7 per month 3.12  0.01  6.80 (5.54) 30.01 
MOLNMolecular Partners AG(0.10)5 per month 4.92 (0.01) 9.38 (7.97) 52.92 
PEPGPepGen 0.39 8 per month 0.00 (0.21) 5.12 (9.02) 26.81 
CYTCyteir Therapeutics 0.09 2 per month 2.57  0.08  10.00 (5.26) 36.14 

NewAmsterdam Pharma Additional Predictive Modules

Most predictive techniques to examine NewAmsterdam price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for NewAmsterdam using various technical indicators. When you analyze NewAmsterdam charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About NewAmsterdam Pharma Predictive Indicators

The successful prediction of NewAmsterdam Pharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as NewAmsterdam Pharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of NewAmsterdam Pharma based on analysis of NewAmsterdam Pharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to NewAmsterdam Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to NewAmsterdam Pharma's related companies.
 2023 2024 (projected)
Graham Number13.0410.2
Receivables Turnover41.737.06

Story Coverage note for NewAmsterdam Pharma

The number of cover stories for NewAmsterdam Pharma depends on current market conditions and NewAmsterdam Pharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that NewAmsterdam Pharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about NewAmsterdam Pharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

NewAmsterdam Pharma Short Properties

NewAmsterdam Pharma's future price predictability will typically decrease when NewAmsterdam Pharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of NewAmsterdam Pharma often depends not only on the future outlook of the potential NewAmsterdam Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. NewAmsterdam Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding82.2 M
Cash And Short Term Investments340.4 M

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.